# The pharmacokinetics of nimodipine, intravenous and orally, in patients with subarachnoidal hemorrhage admitted in the intensive care.

No registrations found.

Ethical review Positive opinion

**Status** Recruitment stopped

Health condition type -

Study type Interventional

# **Summary**

#### ID

NL-OMON21573

Source

**NTR** 

**Brief title** 

Nimodipine subarachnoidal hemorrhage ICU

**Health condition** 

subarachnoidal hemorrhage treatment in intensive care

## **Sponsors and support**

**Primary sponsor:** none

Source(s) of monetary or material Support: none

Intervention

#### **Outcome measures**

#### **Primary outcome**

- 1. Pharmacokinetics of nimodipine in this specific group of patients;
- 2. Variability of bio-availability of orally administred nimodipine.

## **Secondary outcome**

N/A

# **Study description**

## **Background summary**

The pharmacokinetics of nimodipine, intravenous and orally, in patients with subarachnoidal hemorrhage admitted in the intensive care. Use of nimodipine in this specific group of patients according to our SAB protocol. Measurement of nimodipine blood levels during intravenous and orally administration.

## **Study objective**

Describing the pharmacokinetics of nimodipine, especially the variability of bio-availability orally administred nimdipine.

## Study design

N/A

#### Intervention

Bloodsamples according to strict time protocol during treatment.

## **Contacts**

## **Public**

VU medisch centrum Afdeling intensive care volwassenen Boelelaan 1117 B.M. Kors Amsterdam 1081 HV The Netherlands + 31 20 4443900

#### Scientific

2 - The pharmacokinetics of nimodipine, intravenous and orally, in patients with sub ... 5-05-2025

VU medisch centrum
Afdeling intensive care volwassenen
Boelelaan 1117
B.M. Kors
Amsterdam 1081 HV
The Netherlands
+ 31 20 4443900

# **Eligibility criteria**

## Inclusion criteria

- 1. All patients admitted on the ICU with subarachnoidal hemorrhage (SAB), treated according to our SAB-protocol;
- 2. Adults aged 18 70 years old.

## **Exclusion criteria**

- 1. Pregnancy;
- 2. Expected mortality < 24 hours;
- 3. Severe hepatic function disorders;
- 4. Use of medication with know interaction in relation to nimodipine.

# Study design

## **Design**

Study type: Interventional

Intervention model: Other

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

#### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 01-12-2006

Enrollment: 12

Type: Actual

## **Ethics review**

Positive opinion

Date: 19-01-2007

Application type: First submission

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

NTR-new NL861 NTR-old NTR875 Other : N/A

ISRCTN ISRCTN45381163

# **Study results**

## **Summary results**

4 - The pharmacokinetics of nimodipine, intravenous and orally, in patients with sub ... 5-05-2025